Combining this approach with PI3K inhibition, antagonism of the insulin pathway to reduce side effects, and PKC inhibitors could represent an exciting multimodal therapy that targets several key oncogenic pathways in DIPG. This evidence concerns the gene INS and diffuse intrinsic pontine glioma.